Literature DB >> 7636551

Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx.

D A Fein1, W R Lee, A L Hanlon, J A Ridge, C J Langer, W J Curran, L R Coia.   

Abstract

PURPOSE: A number of reports have documented the relationship between pretreatment hemoglobin level and local control and/or survival in the treatment of cervix, bladder, and advanced head and neck tumors. Consideration of correcting anemia before initiation of radiation therapy may prove increasingly important as clinical trials use intensive induction chemotherapy in the treatment of head and neck carcinomas. Neoadjuvant chemotherapy may produce anemia, which in turn may reduce the effectiveness of subsequent irradiation.
MATERIALS AND METHODS: One hundred nine patients with T1-2N0 squamous cell carcinoma of the glottic larynx were treated with definitive radiotherapy at the Fox Chase Cancer Center between June 1980 and November 1990. Follow-up times ranged from 26 to 165 months (median, 82).
RESULTS: The 2-year local control rate for patients who presented with a hemoglobin level < or = 13 g/dL was 66%, compared with 95% for patients with a hemoglobin level more than 13 g/dL (P = .0018). The 2-year survival rate for patients with a hemoglobin level < or = 13 g/dL was 46%, compared with 88% for patients with a hemoglobin level more than 13 g/dL (P < .001). Cox proportional hazards regression analysis showed that hemoglobin level (P = .0016) was the only variable that significantly influenced local control (P = .0016) and survival (P < .0001).
CONCLUSION: Patients who presented with hemoglobin levels more than 13 g/dL had significantly higher local control and survival rates. The strong apparent correlation between hemoglobin level, local control, and survival supports consideration of correcting anemia before initiation of radiation therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7636551     DOI: 10.1200/JCO.1995.13.8.2077

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  18 in total

Review 1.  Impact of anemia in patients with head and neck cancer treated with radiation therapy.

Authors:  Kenneth Hu; Louis B Harrison
Journal:  Curr Treat Options Oncol       Date:  2005-01

2.  Recombinant human erythropoietin (rhEPO) in the prevention and treatment of chemotherapy-induced anaemia.

Authors:  M R Nowrousian
Journal:  Med Oncol       Date:  1998-09       Impact factor: 3.064

3.  [Simultaneous radiochemotherapy with carboplatin in patients with inoperable advanced stage III and IV head and neck tumors].

Authors:  R Mücke; M Blynow; P G Ziegler; T Libera; G Kundt; S Dommerich; B Kramp; R Fietkau
Journal:  Strahlenther Onkol       Date:  1999-05       Impact factor: 3.621

4.  Baseline hemoglobin and liver function predict tolerability and overall survival of patients receiving radioembolization for chemotherapy-refractory metastatic colorectal cancer.

Authors:  Andrew S Kennedy; David Ball; Steven J Cohen; Michael Cohn; Douglas M Coldwell; Alain Drooz; Edward Ehrenwald; Samir Kanani; Fred M Moeslein; Charles W Nutting; Samuel G Putnam; Steven C Rose; Michael Savin; Sabine Schirm; Navesh K Sharma; Eric Wang
Journal:  J Gastrointest Oncol       Date:  2017-02

Review 5.  Clinical and economic impact of epoetins in cancer care.

Authors:  Monia Marchetti; Giovanni Barosi
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

6.  High-grade acute organ toxicity during preoperative radiochemotherapy as positive predictor for complete histopathologic tumor regression in multimodal treatment of locally advanced rectal cancer.

Authors:  Hendrik Andreas Wolff; Jochen Gaedcke; Klaus Jung; Robert Michael Hermann; Hilka Rothe; Markus Schirmer; Torsten Liersch; Markus Karl Alfred Herrmann; Steffen Hennies; Margret Rave-Fränk; Clemens Friedrich Hess; Hans Christiansen
Journal:  Strahlenther Onkol       Date:  2009-12-28       Impact factor: 3.621

Review 7.  The clinical value of erythropoietin in patients with cancer.

Authors:  Ulrich Dührsen
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  The role of intravenous iron in the treatment of anemia in cancer patients.

Authors:  H Tilman Steinmetz
Journal:  Ther Adv Hematol       Date:  2012-06

Review 9.  Old but new methods in radiation oncology: hyperbaric oxygen therapy.

Authors:  Kazuhiko Ogawa; Kiyotaka Kohshi; Syogo Ishiuchi; Masayuki Matsushita; Naoki Yoshimi; Sadayuki Murayama
Journal:  Int J Clin Oncol       Date:  2013-03-05       Impact factor: 3.402

Review 10.  Effects of recombinant erythropoietin on breast cancer-initiating cells.

Authors:  Tiffany M Phillips; Kwanghee Kim; Erina Vlashi; William H McBride; Frank Pajonk
Journal:  Neoplasia       Date:  2007-12       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.